Prostate Cancer Market to Expand "Rapidly" to 2021

November 13, 2015

November 13, 2015.

The global treatment market for prostate cancer will expand rapidly from $7.6 billion in 2014 to $13.6 billion by 2021, according to business intelligence provider GBI Research.

The company’s latest report says that the rise will be driven primarily by growth in disease prevalence due to an aging global population.

Katie Noon, Senior Analyst for GBI Research, says the continued uptake of Zytiga and Xtandi and the approval of several premium products will also be key factors aiding prostate cancer therapy market growth by 2021.

She adds that the prostate cancer therapeutics market will also be boosted by the anticipated approval of nine late-stage pipeline products during the forecast period, including the cancer vaccines Prostvac, DCVAC and ProstAtak.

The report also states that although the therapeutic pipeline for prostate cancer is relatively large, with 448 products in active development, the indication suffers from a high failure rate.

Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth